GTEH GenTech Holdings, Inc. Provides Mid-Year Update:

New Post Public Reply Private Reply Replies (0) Message Board
metalman123
81
GTEH

GenTech Holdings, Inc. Provides Mid-Year Update: Multiple Acquisitions, Debt Reduction, Growth Acceleration
9:15 am ET July 12, 2021 (Globe Newswire) Print
GenTech Holdings, Inc. (OTC Pink: GTEH) ("GenTech" or the "Company" (www.gentechholdings.com), an emerging leader in the Functional Foods marketplace (www.sinfitnutrition.com), is pleased to provide current and prospective shareholders with a 2021 Mid-Year Update, highlighting key accomplishments midway through what Company officials believe to be a pivotal year for GenTech.

Management highlights the Company's recent series of four fully completed value-add acquisitions, including Yourganics (www.yourganicsnutrition.com), MPB Snacks (www.mpbsnacks.com), NxtBar (www.nxtbar.com), and Fizzique (www.drinkfizzique.com). The Company is also in the process of closing a fifth, after signing an LOI to acquire Nature Soothie (NatureSoothie.com). The Company expects to close the Nature Soothie acquisition before the end of July.

The Company has also been proactively engaged in balance sheet improvements driven by a combination of cash from operations and mutually beneficial renegotiations.

During the first half of 2021, the Company has settled with multiple convertible noteholders, removing more than $1 million in convertible notes from the balance sheet. This debt reduction initiative will continue throughout 2021. The Company plans to have no outstanding convertible debentures on its books by the end of Q2 2022. At present, only one major convertible noteholder remains outstanding: 'East Capital Investment Corp'. The Company is actively engaged in proactive discussions with this creditor. The Company announced early in 2021 that it had settled an outstanding judgement of $1.09 million from 2017 at that time.

In total, GenTech has proactively reduced total outstanding liabilities by $2 million, or 62%, so far this year, leaving the Company in a significantly strengthened position as management looks forward to explosive growth potential in 2022.

In addition, the Company has begun to see dramatic sales growth in 2021. As of June 30, leaving out the contributions of recent acquisitions and only focusing on the core SINFIT Nutrition segment, total revenues were approximately $300k during the first half of the year. If acquisitions are included, that number, expressed as a semi-annualized run rate, grows to well over $650k. However, significant additional commercialization involving acquired products will roll out over coming months, pushing that run rate substantially higher by year end.

David Lovatt, GenTech CEO, commented, "The Fizzique acquisition is the most important deal in GenTech history. We have already engaged an outsourced beverage specialist to handle all provisioning, manufacturing, and third-party contract packing. We are ordering 4 million cans - 1 million of each of Fizzique's four flavors - in a production run that should be completed in August, ready to ship. Our topline expectation from this tranche of product exceeds $6 million in SINFIT sales."

Lovatt added, "SINFIT Nutrition has also contracted with an expert outsourced sales agency to secure contracts with major retailers, which we believe is a very feasible plan given our understanding of past negotiations involving Fizzique's products - Fizzique is already approved for sale in Walmart stores, for example. We hope that a production run of approximately 4 million cans of Fizzique each quarter by Q1 of 2022 will become 'run-rate business' for the Fizzique brand. That could give us a conservative 2022 Fizzique sales forecast range of $15-20 million."

SINFIT Nutrition currently has post-acquisition cash assets totaling approximately $3 million, leaving the Company well positioned to drive successful commercial execution of all of the opportunities arising from its 2021 acquisitions.

"It's important to place the past six months in a larger context," concluded Lovatt. "Our consolidated revenues for 2019 were virtually nothing, and we did only approximately $250k in 2020. So, the growth we are seeing this year is huge. Once our cash requirements are met - which we expect to be in very short order - we believe the pressure on our shares will lift and it will have an opportunity to price according to the strong fundamentals we have lined up over recent months, and the growth potential they imply for coming quarters. Hence, we see no need at present for a reverse split."
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sony Expands Versatile Wireless Headphone Lineup: 2026

Updated Category News Views 4

Renewed Focus on Sound: Sony's Latest Headphones Sony's dipping into the headphone market this time with a splash of style and sound signature updates. We've got the WH-1000XM4C, a next-gen version of the top-dog noise-cancelling cans, that are gonna catch the eye of every audiophile and traveler out there. WH-1000XM4C: The Flagship gets a Lift What they're offering is...

Continue Reading
GEEKOM A5 2027: Mini PC Built to Boost Your Game

Updated Category News Views 2

GEEKOM Raises the Bar with A5 2027 Build Every once in a blue moon, a piece of tech pricks up my ears and this time it's the GEEKOM A5 2027 Edition. Released on September 7, 2026, this contraption's not just joining the ranks—it's looking to redefine them. It's geared for the real-world junkie who’s raking through browser tabs, dropping into video meetings, and making...

Continue Reading
Lab Glassware Market Set for Steady Growth by 2031

Updated Category News Views 2

When you dive into the world of laboratory glassware, it might look like it's all pipettes and test tubes, but there's more bubbling under the surface. This market's got its eyes on a neat little climb from $7,630 million in 2026 to a forecasted $9,170 million by 2031. Ain't just speculation—this one's solid muscle growing at a comfortable 4.0% compound annual growth...

Continue Reading
WaFd and EverBank $3.9B Deal Spurs Big Bank Shift

Updated Category News Views 2

Remember the good old days when banking was just about collecting interest? Now it's all about combining forces to bolster strength, and that's just what we're seeing with WaFd, Inc. (NASDAQ: WAFD) and EverBank Financial Corp flipping the script and shaking hands on a $3.9 billion reverse merger. Strategic Vision: A New Chapter They're calling it a 'strategic...

Continue Reading
Hims & Hers Health Hit by FTC Claims and Class Action

Updated Category News Views 3

Hims Faces Harsh Lessons With FTC Lawsuit There's trouble brewing in the world of telehealth, and Hims & Hers Health (NYSE: HIMS) is right at the eye of the storm. They've gone from a darling of digital health to a pariah faster than you can say 'data breach.' On July 29, 2026, they took a hit so hard you’d think the company stepped into the ring with a heavyweight...

Continue Reading
CABP Market Sees Potential in New Treatments Rising

Updated Category News Views 2

Rising Threats and New Solutions in CABP Market Listen up, folks. The community-acquired bacterial pneumonia (CABP) market is set to swell. And why is that? Well, it's got everything to do with a growing disease burden, aging populations, and complications from comorbid conditions. But here's the kicker: antimicrobial resistance is climbing like a cat up a tree, and that...

Continue Reading
West Texas Weather Shapes Home Design Decisions

Updated Category News Views 2

West Texas Weather: A Tough Customer for Home Builders You'd think building a house is a straightforward gig, but slap it down in West Texas, and we're talking a whole different ballgame. With its brutal heat, howling winds, and wild temperature swings, Odessa isn't just painting by numbers. It's where Mother Nature is your uninvited consultant on every single...

Continue Reading
GBC 2026 Wraps Up: Korea Eyes Bio Industry Leadership

Updated Category News Views 3

GBC 2026: Korea's Giant Leap in Bio Innovation Well, there wasn't a dull moment at the 'Global Bio Conference 2026' in Seoul. Picture a melting pot where 5,600 participants from 19 countries converged to chat about the latest and greatest in biopharma innovation and regulatory strategies. That's not a setup you see every day, mind you. This event packed the room with...

Continue Reading
Dentsply Sirona Faces Insider Troubles: An Investor Call

Updated Category News Views 3

Are Dentsply Sirona Insiders on Thin Ice? The stock market's a tumultuous sea, and right now, it seems like some of those at the helm of Dentsply Sirona Inc. might be rocking the boat a bit too much. Let me tell you, navigating these corporate storms isn't for the faint-hearted. The latest noise coming from Halper Sadeh LLC suggests that some directors and officers over...

Continue Reading
DoorDash Speeds Up Gifting: Same-Day Delivery Wins

Updated Category News Views 1

Transforming Urgent Gift-Giving with Local Delivery Ever found yourself scrambling for a last-minute gift when time seems to be slipping away? That's where DoorDash steps up, changing the game with their same-day delivery options. In the fast-paced world we're living in, folks aren't just leaning on DoorDash for takeout anymore. They're pushing it as a lifeline for...

Continue Reading

Top 5 Most Recently Viewed Articles

Discovering Unique Luxury with The Edge List 2025 Highlights

Updated Category News Views 525

Celebrating The Edge List 2025 Forbes Travel Guide has unveiled The Edge List 2025, a captivating selection of luxury hotels, resorts, and cruises that redefine the essence of travel. This prestigious list honors properties that provide remarkable access to secluded and breathtaking destinations, paired with unparalleled comfort and extraordinary experiences. Exploring...

Continue Reading
NATURE Trial Success: enVast Cuts STEMI Infarct Size

Updated Category News Views 72

A New Angle on STEMI Treatment Who would've thought? In the crowded world of cardiovascular treatments, Vesalio just threw their hat into the ring with the enVast Coronary Clot Retriever. This gizmo's making waves after the NATURE trial results came down the pipeline. Dubbed a game-changer, it's shaking up how we tackle hefty thrombus burdens in STEMI patients. If you're...

Continue Reading
Aptose Biosciences Appoints New Auditor Amid Changes

Updated Category News Views 151

Aptose Biosciences Announces Transition in Auditing Firm In a significant move, Aptose Biosciences Inc. (TSX:APS), a clinical-stage precision oncology entity, has revealed that KPMG LLP will not be seeking re-appointment for the upcoming annual audit cycle. This announcement serves as a key development for the company as they progress towards enhancing their financial...

Continue Reading
Liquidity Withdrawal Sparks Crisis for LIBRA Token Investors

Updated Category News Views 250

Liquidity Withdrawal Crisis for LIBRA Token The LIBRA token has been at the center of turmoil after a massive liquidity removal estimated at $99 million, executed by parties connected to its creator, has come to light. This move has left many investors devastated and questioning the integrity of the project. Details of the Liquidity Withdrawal According to a recent...

Continue Reading
UNITS Moving and Portable Storage Earns Esteemed Industry Recognition

Updated Category News Views 110

UNITS Moving and Portable Storage Achieves Top Ranking Newsweek Reader's Choice Poll Showcases Brand's Reliability and Ease of Use UNITS® Moving and Portable Storage proudly announces its recognition as the second-best moving container company in a recent industry poll. This accolade reflects the positive feedback from customers nationwide who trust UNITS for their...

Continue Reading